Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

362 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Novel targets in solid tumors: MEK inhibitors.
Messersmith WA, Hidalgo M, Carducci M, Eckhardt SG. Messersmith WA, et al. Among authors: eckhardt sg. Clin Adv Hematol Oncol. 2006 Nov;4(11):831-6. Clin Adv Hematol Oncol. 2006. PMID: 17143253 Review.
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, Hanson LJ, Gore L, Chow L, Leong S, Maloney L, Gordon G, Simmons H, Marlow A, Litwiler K, Brown S, Poch G, Kane K, Haney J, Eckhardt SG. Adjei AA, et al. Among authors: eckhardt sg. J Clin Oncol. 2008 May 1;26(13):2139-46. doi: 10.1200/JCO.2007.14.4956. Epub 2008 Apr 7. J Clin Oncol. 2008. PMID: 18390968 Free PMC article. Clinical Trial.
A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer.
Zhou Q, Gustafson D, Nallapareddy S, Diab S, Leong S, Lewis K, Gore L, Messersmith WA, Treston AM, Eckhardt SG, Sidor C, Camidge DR. Zhou Q, et al. Among authors: eckhardt sg. Invest New Drugs. 2011 Apr;29(2):340-6. doi: 10.1007/s10637-009-9383-9. Epub 2010 Jan 19. Invest New Drugs. 2011. PMID: 20084425 Free PMC article. Clinical Trial.
Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development.
Pitts TM, Tan AC, Kulikowski GN, Tentler JJ, Brown AM, Flanigan SA, Leong S, Coldren CD, Hirsch FR, Varella-Garcia M, Korch C, Eckhardt SG. Pitts TM, et al. Among authors: eckhardt sg. Clin Cancer Res. 2010 Jun 15;16(12):3193-204. doi: 10.1158/1078-0432.CCR-09-3191. Epub 2010 Jun 8. Clin Cancer Res. 2010. PMID: 20530704 Free PMC article.
Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer.
Arcaroli JJ, Touban BM, Tan AC, Varella-Garcia M, Powell RW, Eckhardt SG, Elvin P, Gao D, Messersmith WA. Arcaroli JJ, et al. Among authors: eckhardt sg. Clin Cancer Res. 2010 Aug 15;16(16):4165-77. doi: 10.1158/1078-0432.CCR-10-0066. Epub 2010 Aug 3. Clin Cancer Res. 2010. PMID: 20682712 Free PMC article.
Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.
Tentler JJ, Nallapareddy S, Tan AC, Spreafico A, Pitts TM, Morelli MP, Selby HM, Kachaeva MI, Flanigan SA, Kulikowski GN, Leong S, Arcaroli JJ, Messersmith WA, Eckhardt SG. Tentler JJ, et al. Among authors: eckhardt sg. Mol Cancer Ther. 2010 Dec;9(12):3351-62. doi: 10.1158/1535-7163.MCT-10-0376. Epub 2010 Oct 5. Mol Cancer Ther. 2010. PMID: 20923857 Free PMC article.
362 results